Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR-AKI
2023-505903-22-00Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial of TIN-816 in sepsis-associated acute kidney injury (S-AKI) (4 arms), sponsored by Novartis. Primary endpoint: Weighted average area under the time-corrected endogenous creatinine clearance curve from Day 1 to Day 8 (AUC1-8). Started May 2024; status: completed.
02
Drugs
TIN-816
03
Conditions
sepsis-associated acute kidney injury (S-AKI)
Beyond the preview
Go deeper on 2023-505903-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505903-22-00.